Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas - PubMed (original) (raw)
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas
Qiulu Pan et al. J Mol Diagn. 2005 Aug.
Abstract
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for approximately 90% of mutated cases: short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 (L858R). Screening for these mutations has been based mainly on direct sequencing. We report here the development and validation of polymerase chain reaction-based assays for these two predominant types of EGFR mutations. The assay for exon 19 mutations is based on length analysis of fluorescently labeled polymerase chain reaction products, and the assay for the exon 21 L858R mutation is based on a new Sau96I restriction site created by this mutation. Using serial dilutions of DNAs from lung cancer cell lines harboring either exon 19 or 21 mutations, we detected these mutations in the presence of up to approximately 90% normal DNA. In a test set of 39 lung cancer samples, direct sequencing detected mutations in 25 cases whereas our assays were positive in 29 cases, including 4 cases in which mutations were not apparent by sequencing. These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors.
Figures
Figure 1
EGFR exon 21 L858R mutation assay design showing primer locations and native and mutant Sau96I restriction enzyme sites.
Figure 2
EGFR exon 19 deletion assay: examples of detection of 9-, 12-, 15-, and 18-bp deletions in EGFR exon 19. The variable relative heights of the deleted and germline peaks may reflect different proportions of tumor cells in these clinical tumor DNAs, or different levels of copy number alterations in the mutated EGFR allele.
Figure 3
Sensitivity analysis of EGFR exon 19 deletion assay using serial dilutions of H1650 cell line DNA into normal DNA. Note that for dilutions of 25% and less the scale has been adjusted to highlight the mutant peak.
Figure 4
EGFR exon 21 L858R mutation assay: examples of undigested, digested germline, and digested mutant PCR products.
Figure 5
Sensitivity analysis of EGFR exon 21 L858R mutation assay using serial dilutions of H1975 cell line DNA into normal DNA. Note that for dilutions of 12.5% and less the scale has been adjusted to highlight the mutant peak.
Similar articles
- EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, Shimizu T, Takeuchi H, Yano M, Fukai I, Fujii Y. Sasaki H, et al. Clin Cancer Res. 2005 Apr 15;11(8):2924-9. doi: 10.1158/1078-0432.CCR-04-1904. Clin Cancer Res. 2005. PMID: 15837743 - Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
Cohen V, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, Tejada NA, Miller WH Jr, Chong G. Cohen V, et al. Cancer. 2006 Dec 15;107(12):2858-65. doi: 10.1002/cncr.22331. Cancer. 2006. PMID: 17096434 - Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer.
Uhara M, Matsuda K, Taira C, Higuchi Y, Okumura N, Yamauchi K. Uhara M, et al. Clin Chim Acta. 2009 Mar;401(1-2):68-72. doi: 10.1016/j.cca.2008.11.018. Epub 2008 Nov 24. Clin Chim Acta. 2009. PMID: 19063875 - Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process.
Hoshi K, Takakura H, Mitani Y, Tatsumi K, Momiyama N, Ichikawa Y, Togo S, Miyagi T, Kawai Y, Kogo Y, Kikuchi T, Kato C, Arakawa T, Uno S, Cizdziel PE, Lezhava A, Ogawa N, Hayashizaki Y, Shimada H. Hoshi K, et al. Clin Cancer Res. 2007 Sep 1;13(17):4974-83. doi: 10.1158/1078-0432.CCR-07-0509. Clin Cancer Res. 2007. PMID: 17785547
Cited by
- Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis.
Chan SK, Choi HC, Lee VH. Chan SK, et al. JTO Clin Res Rep. 2022 Apr 7;3(5):100322. doi: 10.1016/j.jtocrr.2022.100322. eCollection 2022 May. JTO Clin Res Rep. 2022. PMID: 35516725 Free PMC article. - Lung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study.
Hsu F, Sit D, Pastuch A, Dingler A, Atwal P. Hsu F, et al. Clin Transl Radiat Oncol. 2021 Jul 1;30:15-18. doi: 10.1016/j.ctro.2021.06.006. eCollection 2021 Sep. Clin Transl Radiat Oncol. 2021. PMID: 34278010 Free PMC article. - Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate.
Arcila ME, Yang SR, Momeni A, Mata DA, Salazar P, Chan R, Elezovic D, Benayed R, Zehir A, Buonocore DJ, Rekhtman N, Lin O, Ladanyi M, Nafa K. Arcila ME, et al. JTO Clin Res Rep. 2020 Sep;1(3):100077. doi: 10.1016/j.jtocrr.2020.100077. Epub 2020 Jul 18. JTO Clin Res Rep. 2020. PMID: 33511359 Free PMC article. - Rapid EGFR Mutation Detection Using the Idylla Platform: Single-Institution Experience of 1200 Cases Analyzed by an In-House Developed Pipeline and Comparison with Concurrent Next-Generation Sequencing Results.
Momeni-Boroujeni A, Salazar P, Zheng T, Mensah N, Rijo I, Dogan S, Yao J, Moung C, Vanderbilt C, Benhamida J, Chang J, Travis W, Rekhtman N, Ladanyi M, Nafa K, Arcila ME. Momeni-Boroujeni A, et al. J Mol Diagn. 2021 Mar;23(3):310-322. doi: 10.1016/j.jmoldx.2020.11.009. Epub 2020 Dec 18. J Mol Diagn. 2021. PMID: 33346146 Free PMC article.
References
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. - PubMed
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. - PubMed
- Pao W, Miller V, Zakowski MF, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from “never smokers” and correlate with sensitivity of tumors to gefitinib (Iressa) and erlotinib (Tarceva). Proc Natl Acad Sci USA. 2004;101:13306–13311. - PMC - PubMed
- Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004;10:8195–8203. - PubMed
- Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857–865. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous